Will Cellular Biomedicine Group Incorporated (NASDAQ:CBMG) Run Out of Steam Soon? Short Interest Is Down

January 14, 2018 - By Clifton Ray

 Will Cellular Biomedicine Group Incorporated (NASDAQ:CBMG) Run Out of Steam Soon? Short Interest Is Down

Investors sentiment decreased to 0.25 in 2017 Q3. Its down 0.23, from 0.48 in 2017Q2. It fall, as 8 investors sold Cellular Biomedicine Group Inc. shares while 8 reduced holdings. 4 funds opened positions while 0 raised stakes. 562,538 shares or 30.78% less from 812,669 shares in 2017Q2 were reported.
69,100 were reported by Bridgeway Capital Mgmt Incorporated. Lmr Partners Llp, a United Kingdom-based fund reported 14,656 shares. Bnp Paribas Arbitrage owns 0% invested in Cellular Biomedicine Group Inc. (NASDAQ:CBMG) for 7 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% stake. Millennium Mgmt Limited Liability Corp, New York-based fund reported 159,436 shares. Northern Trust Corporation accumulated 0% or 30,036 shares. Blackrock holds 91,422 shares. Dimensional Fund Advsrs Limited Partnership has invested 0% of its portfolio in Cellular Biomedicine Group Inc. (NASDAQ:CBMG). 1,300 are held by Morgan Stanley. Geode Lc holds 42,453 shares or 0% of its portfolio. Deutsche Bancorp Ag reported 123 shares. Element Cap Mngmt Limited Liability Company invested in 21,160 shares. Meeder Asset Management Incorporated has invested 0% of its portfolio in Cellular Biomedicine Group Inc. (NASDAQ:CBMG). Royal Bancorporation Of Canada reported 0% stake. California Public Employees Retirement invested in 0% or 19,000 shares.

The stock of Cellular Biomedicine Group Incorporated (NASDAQ:CBMG) registered a decrease of 0.5% in short interest. CBMG’s total short interest was 239,300 shares in January as published by FINRA. Its down 0.5% from 240,500 shares, reported previously. With 39,400 shares average volume, it will take short sellers 6 days to cover their CBMG’s short positions. The short interest to Cellular Biomedicine Group Incorporated’s float is 2.28%.

The stock increased 9.17% or $1.65 during the last trading session, reaching $19.65. About 108,234 shares traded or 136.37% up from the average. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) has declined 51.66% since January 14, 2017 and is downtrending. It has underperformed by 68.36% the S&P500.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $275.30 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

More notable recent Cellular Biomedicine Group Inc. (NASDAQ:CBMG) news were published by: Globenewswire.com which released: “Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility” on September 22, 2017, also Seekingalpha.com with their article: “Is Cellular Biomedicine Group A Buy?” published on March 21, 2017, Globenewswire.com published: “Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent …” on November 09, 2017. More interesting news about Cellular Biomedicine Group Inc. (NASDAQ:CBMG) were released by: Globenewswire.com and their article: “Cellular Biomedicine Group Executives to Present at Biotech and Money World …” published on October 31, 2017 as well as Globenewswire.com‘s news article titled: “Thermo Fisher Scientific and Cellular Biomedicine Group Announce Strategic …” with publication date: November 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: